Navigation Links
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
Date:12/3/2010

PALO ALTO, Calif., Dec. 3, 2010 /PRNewswire/ -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.  Of the 500,000-1.5 million Parkinson's patients in the United States, about 50% experience incidence of levodopa-induced dyskinesias (LIDs), for which there are no approved treatments.  NP002 is a small molecule, orally available nicotinic receptor agonist that has been shown in preclinical studies to reduce LIDs without affecting Parkinsonian symptoms.

A double blinded, placebo controlled, Phase 1/2 study was performed to assess the safety and tolerability of NP002 in a total of 65 individuals with Parkinson's disease and documented LIDs.  The primary objective of the study was the establishment of safety and tolerability of NP002, with patients being assessed over a 14-week treatment and monitoring period.  The secondary objective was to investigate the effects of NP002 on a set of Parkinson's disease and dyskinesia assessment scales, including The Unified Parkinson's Disease Rating Scale (UPDRS), the Unified Dyskinesia Rating Scale (UDRS), the Lang-Fahn Activities of Daily Living Scale (LF-ADL), and the clinician and patient global impressions of change scales (CGIC and PGIC).

NP002 administered concurrently with levodopa treatment was found to be generally safe and well-tolerated in Parkinson's patients with LIDs.  In addition, NP002 was not associated with any impulsivity or withdrawal issues when compared to placebo.  Although the trial was not powered as an efficacy study, clinically relevant trends and, in two cas
'/>"/>

SOURCE Neuraltus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
2. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
3. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
4. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
5. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
6. Onyx Pharmaceuticals Announces December 2010 Investor Events
7. Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes
8. Prolong Pharmaceuticals Boosts Executive Team
9. Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection
10. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
11. Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provids Unique MS Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... 2014 Unbound , an international humanitarian ... regions of the Philippines being affected by both a tropical ... families evacuated to the nearest public schools while others moved ... and gusty winds to portions of the northern Philippines. ... homes filled with more than 10 feet of water. ...
(Date:9/19/2014)... Phoenix, AZ (PRWEB) September 19, 2014 Hastings ... over 30 years in the industry, announces a record number ... firm handles a wide variety of serious injury cases as ... cases along with dog bite related accident cases and others. ... Hastings and Hastings has stood the test of time when ...
(Date:9/19/2014)... U.S. military troops deployed to sunny climates may have ... new study. Many returning troops reported getting ... military personnel developed blisters on their skin or noticed ... their moles since being deployed overseas. All of ... the study authors noted. "The past decade of ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... Cancer patients burdened by stress and family conflicts before ... their operation, a new study suggests. Investigators found ... have a nearly three times greater risk for complications ... of life. "We,ve long known that patient quality ...
(Date:9/19/2014)... Pittsburgh, PA (PRWEB) September 19, 2014 ... I fear getting wrinkles due to stretching the skin ... from Anniston, Ala. "This inspired me to design a ... HANDS-FREE EYE CONTACT LENS SYSTEM provides a quicker, easier, ... eliminates the need to perform this task manually, saves ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3
... , WASHINGTON, June 23 Today the 400,000-strong ... Manufacturers of America (PhRMA) for its commitment to ... 50 percent for seniors who fall into the ... Phillips, RetireSafe President, called the commitment, "a huge ...
... disorders are frequently seen as psychological or societal,diseases, but ... study,shows that the levels of a brain protein differ ... and occasionally fatal eating disorder most commonly,affecting women. Scientists ... some studies suggest a link to low levels of ...
... Derma Sciences, Inc. (OTC Bulletin Board: ... today that it has begun shipping BIOGUARD(TM) Barrier Dressings ... has been awarded reimbursement codes for the dressings, allowing ... will offer surgeons, wound care clinicians, infection control experts ...
... Pa., June 23 The Department of Health has received ... Housing and Urban Development, or HUD, to implement a new ... in Erie and Philadelphia. , , "The Healthy ... housing related hazards for children such as mold, radon, and ...
... ... Vivacare has included medication rebate coupons and medication brochures as ... the needs of physicians and patients, and improve medication adherence. 69% ... help them to fill their medication at the pharmacy. 86% of ...
... /PRNewswire-Asia/ -- Wan (Corporate Services) Ltd., the,sole agent of Perrier in Hong ... Perrier. , Perrier Clarifies ... We strongly believe the Consumer Council Findings is not correct. , ... Nitrite in Perrier is,not correct. , Nitrite content ...
Cached Medicine News:Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 2Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 4Health News:Pennsylvania Department of Health Receives Recovery Funds for New Healthy Homes Program 2Health News:Vivacare Patient Education Service Includes Medication Rebates and Brochures to Improve Medication Adherence 2Health News:Vivacare Patient Education Service Includes Medication Rebates and Brochures to Improve Medication Adherence 3Health News:Perrier Clarifies the NITRITE Level in Consumer Council Findings 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
Medicine Products: